JP2019534317A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019534317A5 JP2019534317A5 JP2019533260A JP2019533260A JP2019534317A5 JP 2019534317 A5 JP2019534317 A5 JP 2019534317A5 JP 2019533260 A JP2019533260 A JP 2019533260A JP 2019533260 A JP2019533260 A JP 2019533260A JP 2019534317 A5 JP2019534317 A5 JP 2019534317A5
- Authority
- JP
- Japan
- Prior art keywords
- isolated
- amino acid
- purified
- proteinaceous molecule
- lsd1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims 28
- 102100024985 Lysine-specific histone demethylase 1A Human genes 0.000 claims 11
- 125000000539 amino acid group Chemical group 0.000 claims 10
- 101001050886 Homo sapiens Lysine-specific histone demethylase 1A Proteins 0.000 claims 9
- 229940079593 drug Drugs 0.000 claims 8
- 239000000427 antigen Substances 0.000 claims 6
- 102000036639 antigens Human genes 0.000 claims 6
- 108091007433 antigens Proteins 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 6
- 102000003923 Protein Kinase C Human genes 0.000 claims 5
- 108090000315 Protein Kinase C Proteins 0.000 claims 5
- 102000004169 proteins and genes Human genes 0.000 claims 5
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 239000012528 membrane Substances 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 229940123628 Lysine (K)-specific demethylase 1A inhibitor Drugs 0.000 claims 2
- 101710131866 Protein LSD1 Proteins 0.000 claims 2
- 238000006243 chemical reaction Methods 0.000 claims 2
- 210000002782 epithelial mesenchymal cell Anatomy 0.000 claims 2
- 230000002519 immonomodulatory effect Effects 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 238000012423 maintenance Methods 0.000 claims 2
- 208000037819 metastatic cancer Diseases 0.000 claims 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 2
- 230000007498 myristoylation Effects 0.000 claims 2
- 230000035755 proliferation Effects 0.000 claims 2
- 210000000130 stem cell Anatomy 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 claims 2
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 1
- 206010055113 Breast cancer metastatic Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims 1
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 1
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims 1
- 102000001892 Protein Kinase C-theta Human genes 0.000 claims 1
- 108010015499 Protein Kinase C-theta Proteins 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 230000002584 immunomodulator Effects 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000005937 nuclear translocation Effects 0.000 claims 1
- 230000026731 phosphorylation Effects 0.000 claims 1
- 238000006366 phosphorylation reaction Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2016903602A AU2016903602A0 (en) | 2016-09-07 | Inhibitors and uses therefor | |
| AU2016903602 | 2016-09-07 | ||
| PCT/AU2017/050969 WO2018045422A1 (en) | 2016-09-07 | 2017-09-07 | Lysine specific histone demethylase-1 inhibitors and uses therefor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019534317A JP2019534317A (ja) | 2019-11-28 |
| JP2019534317A5 true JP2019534317A5 (enExample) | 2021-03-04 |
Family
ID=61561256
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019533260A Pending JP2019534317A (ja) | 2016-09-07 | 2017-09-07 | リジン特異的ヒストンデメチラーゼ−１阻害剤及びその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220040280A1 (enExample) |
| EP (1) | EP3509627A4 (enExample) |
| JP (1) | JP2019534317A (enExample) |
| CN (1) | CN110312522A (enExample) |
| AU (1) | AU2017323868A1 (enExample) |
| CA (1) | CA3035806A1 (enExample) |
| SG (1) | SG11201901624RA (enExample) |
| WO (1) | WO2018045422A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102095104B1 (ko) * | 2018-04-24 | 2020-04-23 | 서울대학교산학협력단 | PKCα-LSD1-NFκB 경로를 표적으로 하는 염증반응 조절제 스크리닝 방법용도 |
| EP3636284A1 (en) * | 2018-10-11 | 2020-04-15 | NBE Therapeutics AG | Binding protein-toxin conjugates comprising anthracyclines, and use thereof in immune-oncological applications |
| CN110142068B (zh) * | 2019-06-12 | 2024-02-02 | 杭州华得森生物技术有限公司 | 一种上皮间质混合型循环肿瘤细胞检测试剂盒及方法 |
| US12429477B2 (en) | 2019-09-03 | 2025-09-30 | The Council Of The Queensland Institute Of Medical Research | Methods and agents for determining patient status |
| CN112326961B (zh) * | 2020-10-30 | 2021-08-06 | 福州迈新生物技术开发有限公司 | 一种非小细胞肺癌中pd-l1阳性肿瘤细胞比例的分析方法和存储设备 |
| WO2023067058A1 (en) * | 2021-10-20 | 2023-04-27 | Queen Mary University Of London | Sequential treatments and biomarkers to reverse resistance to kinase inhibitors |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2591717A1 (en) * | 2004-12-16 | 2006-07-06 | President And Fellows Of Harvard College | Histone demethylation mediated by the nuclear amine oxidase homolog lsd1 |
| US7858395B2 (en) * | 2005-07-13 | 2010-12-28 | Universitaetsklinikum Freiburg | Antibodies for use in identifying and/or scoring prostate cancer and androgen receptor-dependent gene expression control |
| WO2012009475A1 (en) * | 2010-07-14 | 2012-01-19 | Oregon Health & Science University | Methods of treating cancer with inhibition of lysine-specific demethylase 1 |
| US20120108500A1 (en) * | 2010-10-07 | 2012-05-03 | Naoki Sakane | Compositions and Methods for Modulating Immunodeficiency Virus Transcription |
| EP2906602B1 (en) * | 2012-10-12 | 2019-01-16 | The General Hospital Corporation | Transcription activator-like effector (tale) - lysine-specific demethylase 1 (lsd1) fusion proteins |
| CA2916533C (en) * | 2013-06-25 | 2022-12-20 | University Of Canberra | Methods and compositions for modulating cancer stem cells |
| US9186391B2 (en) * | 2013-08-29 | 2015-11-17 | Musc Foundation For Research Development | Cyclic peptide inhibitors of lysine-specific demethylase 1 |
| EP3185858A4 (en) * | 2014-08-25 | 2017-12-27 | University of Canberra | Compositions for modulating cancer stem cells and uses therefor |
| JP2019500394A (ja) * | 2015-12-30 | 2019-01-10 | ノバルティス アーゲー | 有効性が増強された免疫エフェクター細胞治療 |
-
2017
- 2017-09-07 EP EP17847815.2A patent/EP3509627A4/en not_active Withdrawn
- 2017-09-07 CN CN201780068891.6A patent/CN110312522A/zh active Pending
- 2017-09-07 WO PCT/AU2017/050969 patent/WO2018045422A1/en not_active Ceased
- 2017-09-07 JP JP2019533260A patent/JP2019534317A/ja active Pending
- 2017-09-07 SG SG11201901624RA patent/SG11201901624RA/en unknown
- 2017-09-07 AU AU2017323868A patent/AU2017323868A1/en not_active Abandoned
- 2017-09-07 CA CA3035806A patent/CA3035806A1/en active Pending
- 2017-09-07 US US16/330,628 patent/US20220040280A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019534317A5 (enExample) | ||
| Buffalo et al. | How HIV Nef proteins hijack membrane traffic to promote infection | |
| Zhang et al. | Human T-cell lymphotropic virus type 1 and its oncogenesis | |
| Zhou et al. | Sensitivity to vaccines, therapeutic antibodies, and viral entry inhibitors and advances to counter the SARS-CoV-2 Omicron variant | |
| Verhelst et al. | Mx proteins: antiviral gatekeepers that restrain the uninvited | |
| SG181523A1 (en) | Therapeutic compounds and related methods of use | |
| Willett et al. | FIV infection of the domestic cat: an animal model for AIDS | |
| Kumar et al. | Anti-SARS coronavirus agents: a patent review (2008–present) | |
| EA007984B1 (ru) | ПОЛИПЕПТИДЫ TACIs И BR3 И ИХ ПРИМЕНЕНИЕ | |
| Ohkoshi et al. | Oncogenic role of p21 in hepatocarcinogenesis suggests a new treatment strategy | |
| EA027040B1 (ru) | Модулирующие иммуносупрессию соединения | |
| JP2016515561A5 (enExample) | ||
| CN107281210B (zh) | 阿奇霉素在抗冠状病毒感染中的应用 | |
| EA200900184A1 (ru) | 4-амино-4-оксобутаноиловые пептиды как ингибиторы вирусной репликации | |
| CA2787309A1 (en) | Hepatitis c virus inhibitors | |
| MX2009010965A (es) | Péptidos de tem8 y vacunas que los contienen. | |
| Suprunenko et al. | Complexities of type I interferon biology: Lessons from LCMV | |
| CN101631780A (zh) | 用于抗病毒治疗的吩噻嗪衍生物 | |
| Gómez et al. | Junín virus. A XXI century update | |
| RU2018142174A (ru) | Контролируемая пищевым рационом экспрессия нуклеиновой кислоты, кодирующей нуклеазу cas9, и ее применения | |
| US7604804B2 (en) | Enhancing anti-HIV efficiency through multivalent inhibitors targeting oligomeric gp120 | |
| Jayaram et al. | The virion N protein of infectious bronchitis virus is more phosphorylated than the N protein from infected cell lysates | |
| AU2018269937A1 (en) | Methods for modifying endoplasmic reticulum processing of protein | |
| JP2019505210A5 (enExample) | ||
| RU2018126487A (ru) | Противораковые вакцины |